NATCOPHARM

Natco Pharma Limited
Small-capHealthcare ↗

What the six lenses say about NATCOPHARM — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.

Price
₹838.3
2026-09-08
VWAP · 1Y anchor
₹928
-9.6% from VWAP
P/E · TTM
10.6×
TTM EPS ₹79.2
52-week range
11%
position low→high
RSI(14)
32
momentum

Own sector index

Healthcare ↗
Neutral

1M

-1.1%

3M

+7.1%

1Y

+14.5%

Breadth >EMA21

55%

How NATCOPHARM’s own sector index is moving — context for reading the stock’s six lenses.

Six-lens read

What the six lenses say

How the lenses are scored ↗
Strength
6.0
avg conviction decile
Leadership
—
top-decile composite in cohort
Each lens is a decile within its cap cohort (D10 = top 10%) — no black-box composite. Expand a lens for the real numbers behind it.
LensDecile · Small-cap cohortDRaw
TechnicalD23›

The actual numbers

Price vs VWAP (1y)-9.6%
EMA trend stackDown · 21<50<200
Price vs 200-EMA-11.0%
Price vs 50-EMA-7.1%
RSI(14)32
RS vs Nifty 500 · 3M-7.9%
RS vs sector · 3M-10.6%
52-week range11%
Volume vs 30d avg0.71×
Volume vs 60d avg0.59×
ATR(14) · volatility22.9
Bollinger width · vol contraction0.116
FundamentalD446›

The actual numbers

Return on equity (ROE)16.9%
Return on capital (ROCE)17.1%
Operating margin37.5%
Net margin34.8%
Revenue growth · YoY-7.9%
EPS growth · YoY-24.8%
Debt / equity0.08×

Full 8-quarter history in the financials table below.

ValuationD1081›

The actual numbers

P/E (TTM)10.6×
TTM EPS₹79.2
52-week range11%
CatalystD846›

The actual numbers

Earnings & momentum60
Capital actions9
Governance70

Every filing in the corporate-announcements panel below.

FlowD1060›

The actual numbers

Promoter holding49.4%
Delivery · 30d avg48.8%
Up/down-day asymmetry-1.0pp
How the decile & conviction are calculated

Decile — each lens’s 0–100 score is ranked against every Small-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.

Conviction — the average of the two active conviction-lens deciles (Technical & Flow):

( D2 + D10 ) ÷ 2 = 6.0(Technical · Flow)

Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.

Glass box

How the score is built

Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.

Conviction score · Below threshold
8
Conviction score 8/100 · avg-decile strength 6.0/10

Policy

Government policy · Healthcare

Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.

Tailwind· HIGH impact

PLI Scheme — Pharmaceuticals & API

Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices

Relative strength · always on

Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-09-08.

Baseline1D1W1M3M6M12M
Nifty 50
Large-cap anchor
+1.7pp
+0.9pp
-4.7pp
-6.3pp
-15.0pp
+3.1pp
Nifty 500
Broad-market baseline
+1.6pp
+0.9pp
-5.7pp
-7.9pp
-20.8pp
-2.1pp
Sector
Own-sector index
—
—
-7.1pp
-10.6pp
-29.5pp
-15.4pp

From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).

Trend

Price · EMA 20 / 50 / 200

NATCOPHARM daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.

₹ (close)
838.30+9.65

Relative strength

RS vs baseline · rebased to 100

NATCOPHARM ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.

RS vs Nifty 500 (=100)
55.03+0.86

TradingView composite technical analysis — multi-timeframe consensus

Quarterly financials

Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.

MetricJun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26
Revenue (₹cr)1,3631,3714751,2211,3291,363647739
↳ change QoQ—+0.6%-65.4%+157.2%+8.8%+2.6%-52.5%+14.2%
EBITDA (₹cr)853868215548571579159128
EBITDA margin62.6%63.3%45.3%44.9%43.0%42.5%24.6%17.3%
PAT (₹cr)669677132406480518151269
↳ change QoQ—+1.2%-80.4%+206.6%+18.2%+7.9%-70.8%+78.1%
Net margin49.1%49.3%27.9%33.3%36.1%38.0%23.3%36.4%
EPS (₹)37.3237.817.4322.7026.8428.948.4614.96
D/E————————
YoY growth · Mar '26Revenue -39.5% YoYPAT -33.7% YoY

Corporate announcements

Filings to the exchange — capital actions, earnings and governance. Most recent first.

  • 9 Sep '26
    LOWgovernance
    Rights Issue

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 9 Sep '26
    HIGHearnings
    Outcome of Board Meeting

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 2 Sep '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 25 Aug '26
    MEDIUMcapital
    Press Release

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 24 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 21 Aug '26
    MEDIUMcapital
    Press Release

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 19 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 19 Aug '26
    MEDIUMearnings
    Investor Presentation

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 18 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 16 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 14 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 14 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 14 Aug '26
    HIGHearnings
    Outcome of Board Meeting

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 11 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 18 Jul '26
    MEDIUMcapital
    Press Release

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗

…and 5 more.

Ownership

Who holds NATCOPHARM

Mutual funds holding NATCOPHARM (5)

FundWeightAUM ₹crGrade
Sundaram Small Cap Gr1.44%3,922
Bandhan Multi Cap Reg Gr0.75%3,064
Samco Flexi Cap Reg Gr2.67%266
The Wealth Company Flexi Cap Reg Gr1.36%247
LIC MF Eq Savings Gr0.55%38

ETFs holding NATCOPHARM (3)

ETFWeightGrade
Zerodha Nifty Smallcap 100 ETF0.70%
Mirae Asset Nifty 500 Healthcare ETF0.59%
Motilal Oswal BSE Healthcare ETF0.52%
Show company profile (about, sector, employees, IPO)
Native from atlas_foundation — lens journal, technical_daily, ohlcv_stock; TradingView for the live instrument view. ← Back to Healthcare